⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DMAC News
DiaMedica Therapeutics Inc. Common Stock
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
DMAC
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
businesswire.com
DMAC
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
businesswire.com
DMAC
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
businesswire.com
DMAC
Form 8-K
sec.gov
DMAC
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
businesswire.com
DMAC
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
businesswire.com
DMAC
Form 8-K
sec.gov
DMAC
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com
DMAC
RedChip's Biotech Virtual Investor Conference Replays Now Available
accessnewswire.com
INAB
DMAC
NSRX
CLDI